ArticleNature2024
Base-editing mutagenesis maps alleles to tune human T cell functions.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Large serine recombinase-mediated gene insertion for high-throughput screens: advantages, design principles, and applications.Nucleic acids research · 2026Review
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Integrated epigenetic and genetic programming of primary human T cells.Nature biotechnology · 2026Article
- Article
- Deciphering protein mutation-phenotype linkages from CRISPR-based tiling mutagenesis screens.Cell systems · 2026Article
- Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.Nature biotechnology · 2026Article
- Mechanistic machine learning for prediction of prime editing outcomes.Nature biotechnology · 2026Article
- High-diversity base mutagenesis via simultaneous adenine, cytosine and guanine editing.Nature communications · 2026Article
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells.Cell reports · 2026Article
- Uncovering functional variants using a high-efficiency PE3-based screening platform.Science advances · 2026Article
- A community machine learning challenge to predict the effects of gene perturbations on T cell differentiation for cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Engineered dCas12f1-SAM enables robust transcriptional activation and gain-of-function screening in primary human cells.Nature communications · 2026Article
- CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges.Molecular biotechnology · 2026Review
- BEstimate: a computational tool for the design and interpretation of CRISPR base editing experiments.Genome biology · 2026Article
- Inducible, split base editors for in vivo cancer functional genomics.Nature biotechnology · 2026Article
- Single-cell and spatial profiling in cancer biology and clinical oncology.Nature cancer · 2026Review
- Mechanistic machine learning enables interpretable and generalizable prediction of prime editing outcomes.bioRxiv : the preprint server for biology · 2026Article
- CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.Nature cancer · 2026Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 3 countries.
Ralf Schmidt *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. ralf.schmidt@meduniwien.ac.at.ORCID 0000-0002-6697-0363
Carl C Ward *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. carl.ward@gladstone.ucsf.edu.ORCID 0000-0002-1188-4839
Rama DajaniGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-8479-8800
Zev Armour-GarbGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Mineto OtaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0003-4552-8573
Vincent AllainGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Rosmely HernandezGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Madeline LayeghiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Galen XingGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Laine GoudyGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Dmytro DorovskyiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Charlotte WangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Yan Yi ChenGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Chun Jimmie YeGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Brian R ShyGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-9569-3708
Luke A GilbertUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5854-0825
Justin EyquemGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-8262-1190
Jonathan K PritchardDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID 0000-0002-8828-5236
Stacie E DodgsonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-6622-5507
Alexander MarsonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. alex.marson@gladstone.ucsf.edu.ORCID 0000-0002-2734-5776
Gladstone Institutes · USStanford University · USUniversity of California, San Francisco · US
Funding
Inherited T cell defects: Diagnosis, Mechanisms and TreatmentsP01AI138962 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSON, ALEXANDER · 2020 to 2024
$11.3MSTAT3 variants as a rheostat of immune toleranceP01AI155393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mark S Anderson · 2022 to 2026
$10.5MMolecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MRESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2MIntegration of genetic association mapping and functional data to elucidate genetic mechanisms of diseaseR01HG008140 · NHGRI · STANFORD UNIVERSITY · PI JONATHAN K PRITCHARD · 2016 to 2026
$7.3MIdentification and characterization of inflammatory bowel disease causal variantsR01DK129364 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Hailiang Huang · 2022 to 2026
$3.4MA GENETIC INTERACTION MAP OF THE HUMAN NUCLEUSDP2CA239597 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GILBERT, LUKE · 2018 to 2018
$2.4MNon-viral genome, epigenome, and transcriptome engineering for clinical CAR-T cell manufacturingK08CA273529 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian R Shy · 2022 to 2026
$1.2MIllumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583kBD FACSAria II Flow CytometerS10RR028962 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI CAVROIS, MARIELLE · 2011 to 2011
$544kANTI-GP120 ANTIBODIES RECOGNIZING THE CCR5 BINDING SITER21AI055393 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI FARZAN, MICHAEL R. · 2003 to 2004
$483kExpanding the scope of protein degradation and stability using chemoproteomic platformsK00CA245718 · NCI · J. DAVID GLADSTONE INSTITUTES · PI WARD, CARL · 2021 to 2024
$371kNCATS NIH HHS L30 TR002983NCI NIH HHS DP2 CA239597NCI NIH HHS K00 CA245718NCI NIH HHS K08 CA273529NCI NIH HHS T32 CA108462NCRR NIH HHS S10 RR028962NHGRI NIH HHS R01 HG008140NIAID NIH HHS P01 AI138962NIAID NIH HHS P01 AI155393NIAID NIH HHS R21 AI055393NIAMS NIH HHS P30 AR070155NIDDK NIH HHS R01 DK129364NIH HHS S10 OD028511
Abstract
CRISPR-enabled screening is a powerful tool for the discovery of genes that control T cell function and has nominated candidate targets for immunotherapies
Indexed as
AllelesGene EditingMutagenesisT-LymphocytesAdaptor Proteins, Signal TransducingAmino AcidsClass I Phosphatidylinositol 3-KinasesCRISPR-Cas SystemsCytokinesGain of Function MutationHumansLoss of Function MutationLymphocyte ActivationPhospholipase C gammaPhosphoproteinsProto-Oncogene Proteins c-vavAdaptor Proteins, Signal TransducingAmino AcidsClass I Phosphatidylinositol 3-KinasesCytokinesPhospholipase C gammaPhosphoproteinsPIK3CD protein, humanPLCG2 protein, humanProto-Oncogene Proteins c-vavRNA, Guide, CRISPR-Cas SystemsSLP-76 signal Transducing adaptor proteinsVAV1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.